• Profile
Close

Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN Solid Tumor Trial

JAMA Jan 09, 2019

Hassan R, et al. - Authors assessed 53 patients (median age of 67 years) to evaluate the effectiveness and safety of avelumab (10 mg/kg, every 2 weeks until disease progression or unacceptable toxic effects) in those with previously treated mesothelioma in this phase 1b open-label study. They observed durable responses in candidates with anti-programmed cell death ligand 1 (PD-L1)–positive tumors and PD-L1–negative tumors, based on a 5% or greater PD-L1 cutoff. They also noted a 58% disease control rate with median progression-free survival (PFS) of 4.1 months and the 12-month PFS rate of 17.4%. A median overall survival (OS) of 10.7 months and the median 12-month OS rate of 43.8% were also found with no treatment-related deaths. An acceptable safety profile was seen with avelumab, with durable antitumor activity and disease control.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay